Starpharma Holdings Gross Profit 2011-2021 | SPHRY

Starpharma Holdings gross profit from 2011 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Starpharma Holdings Annual Gross Profit
(Millions of US $)
2021 $2
2020 $4
2019 $2
2018 $4
2017 $3
2016 $3
2015 $1
2014 $1
2013 $2
2012 $3
2011 $2
Starpharma Holdings Quarterly Gross Profit
(Millions of US $)
2021-12-31
2021-06-30
2020-12-31
2020-06-30
2019-12-31
2019-06-30
2018-06-30
2017-12-31
2017-06-30
2016-12-31
2016-06-30
2015-06-30
2014-12-31
2014-06-30
2013-12-31
2013-06-30
2012-12-31
2012-06-30
2011-12-31
2011-06-30
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.231B $0.002B
Starpharma Holdings Limited is engaged in the development of dendrimer products for pharmaceutical, life science and other applications. The Company's primary product in development is VivaGel, a microbicide gel for women used for the prevention and treatment of bacterial vaginosis and a range of sexually transmitted diseases. It also develops dendrimers as specialty chemicals for industrial applications. Starpharma Holdings Limited is headquartered in Melbourne, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $159.141B 9.65
GSK (GSK) United Kingdom $71.077B 8.53
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.276B 18.88
Biohaven Pharmaceutical Holding (BHVN) United States $10.581B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.200B 0.00
Arcus Biosciences (RCUS) United States $2.020B 39.44
Myovant Sciences (MYOV) United Kingdom $1.765B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.81
Zymeworks (ZYME) Canada $0.418B 0.00
Enzo Biochem (ENZ) United States $0.133B 0.00
Gelesis Holdings (GLS) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00